modelN06BA12
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Lisdexamfetamine | |
| ATC code: | N06BA12 | route: | oral |
| compartments: | 1 | |
| dosage: | 70 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 0.4 | L/hr/kg |
| other parameters in model implementation | ||
Lisdexamfetamine is a prodrug of the central nervous system stimulant dextroamphetamine. It is primarily used for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults and is also approved for the treatment of moderate to severe binge eating disorder in adults. It is currently approved and in clinical use.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers following a single oral dose.
References
Boellner, SW, et al., & Zhang, Y (2010). Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clinical therapeutics 32(2) 252–264. DOI:10.1016/j.clinthera.2010.02.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20206783
Tsuda, Y, et al., & Wajima, T (2020). Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients. Drug metabolism and pharmacokinetics 35(6) 548–554. DOI:10.1016/j.dmpk.2020.08.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33082099
Ermer, J, et al., & Matsuo, Y (2020). A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects. Neuropsychopharmacology reports 40(1) 16–29. DOI:10.1002/npr2.12082 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31765110
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)